Alan Walshe Thanks PPTA on Behalf of Plasma Donors And Patients Who Rely on PDMPs
Alan Walshe, Senior Vice President, Head of Global Commercial Strategy for Plasma Derived Therapies at Takeda, reposted from Anita Brikman on LinkedIn:
”This year’s Plasma Protein Forum, taking place in Washington DC, is tackling the most urgent issues facing Plasma-Derived Medicinal Products (PDMPs) including growing patient need, plasma donor health and the vital importance of partnering with regulators and other stakeholders.
Thank you Plasma Protein Therapeutics Association (PPTA) for your important work on behalf of plasma donors and patients who rely on PDMPs.”
Quoting Anita Brikman‘s post:
”Day one of the Plasma Protein Forum set a powerful tone for collaboration, innovation, and impact across the plasma community.
Plasma Protein Therapeutics Association (PPTA) Global Executive Board Chair Giles Platford began the day by reminding attendees of the importance of science-driven progress and global partnership.
Dr. Namandje Bumpus continued that discussion by delivering a collaborative keynote on regulatory excellence.
Sessions then moved to thought-provoking examinations on trade, donor health, state policy, and innovation.
Each session underscored the industry’s shared commitment to donors and patients.
A special thank you to all speakers, moderators, and sponsors who made today’s sessions and networking moments so engaging.
I am excited to see what tomorrow will bring at PPF2025.”
More from PPF2025 featured in Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis